Chids Mahadevan - Applied Therapeutics Sr Officer

Applied Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.7601) % which means that it has lost $0.7601 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7339) %, meaning that it created substantial loss on money invested by shareholders. Applied Therapeutics' management efficiency ratios could be used to measure how well Applied Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Applied Therapeutics' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 7.33 in 2024, whereas Return On Tangible Assets are likely to drop (2.29) in 2024. At this time, Applied Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 56.5 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 681.3 K in 2024.

Similar Executives

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Applied Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people. Applied Therapeutics (APLT) is traded on NASDAQ Exchange in USA. It is located in 545 Fifth Avenue, New York, NY, United States, 10017 and employs 37 people. Applied Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Applied Therapeutics Leadership Team

Applied Stock Performance Indicators

Additional Tools for Applied Stock Analysis